Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 57

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 57
---
 categorized into four key areas, with weighting and objectives as follows:

| • |     | 20% Financial: Balance sheet metrics, consisting of target cash balances; |

56

| • |     | 30% Commercial: Net product revenue, market access, and conversion of U.S. Expanded Access Program participants; |

| • |     | 30% Pipeline: Product approval and advancement of other clinical candidates; and |

| • |     | 20% Corporate: Strategic plan, expansion of investor relations activities and talent management. |

Additionally, the Company offers bonus enhancements of up to an additional 40% tied to exceeding market capitalization growth and other performance targets. For 2024, the Board determined that the corporate objectives were achieved at 129.5% of target. Specifically, the financial targets were achieved at 75% of target (weighted total of 15.0%), the commercial targets were achieved at 89% of target (weighted total of 26.6%), the pipeline targets were achieved at 100% of target (weighted total of 30.0%), the corporate targets were achieved at 125% of target (weighted total of 25.0%), and the bonus enhancement target was achieved at 32.9% of target (weighted total of 32.9%). The actual amounts paid to our NEOs under our 2024 annual cash bonus program are set forth in the 2024 Summary Compensation Table below. Our Compensation Committee periodically reviews NEO target bonus amounts in consultation with management and the committee’s compensation consultant to determine whether any adjustments are necessary or appropriate. The NEOs’ 2025 target annual cash bonus opportunities are unchanged from 2024. Long-TermIncentive Compensation Our Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”) and our 2023 Employment Inducement Award Plan (the “2023 Plan”) authorize us to make grants to eligible recipients of stock options, restricted stock units and other stock-basedawards. All of our awards granted in 2024 under these plans were in the form of stock options and restricted stock units. We typically grant stock options at the start of employment to each executive and our other employees. Additionally, the Compensation Committee may grant additional equity in its discretion to provide additional targeted grants in appropriate circumstances, such as in connection with an employee taking on a new role at the Company. Typically, our stock options vest in equal annual installments over a period of four years, subject to continued service